Pliant Therapeutics Inc（PLRX）财务数据PLRXPliant Therapeutics Inc

Evaluating the bottom line, Pliant Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -50.29%, provide a clear picture of how effectively PLRX converts its operational activities into shareholder value.

In the context of the broader market, PLRX competes directly with industry leaders such as HYFT and HRTX. With a market capitalization of $49.93M, it holds a significant position in the sector. When comparing efficiency, PLRX's gross margin of N/A stands against HYFT's 58.58% and HRTX's 69.28%. Such benchmarking helps identify whether Pliant Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Pliant Therapeutics has consistently reported negative earnings, with a net income loss of $49.7 million in Q4 2024 and a forward P/E ratio of 0, indicating no expected profitability in the near term. The gross profit remains at zero, reflecting ongoing operational challenges.